Amgen’s Otezla And BMS’s Sotyktu Battle For Share In Oral Psoriasis Drug Market
Q4 Was First Full Quarter BMS’s TYK2 Inhibitor Was Available
Executive Summary
Amgen and Bristol defended their positions in the post-topical/pre-biologic segment of the psoriasis market during their Q4 earnings calls, now that each company has an oral drug available.
You may also be interested in...
As BMS Braces For Major LOEs, It All Comes Down To Execution
As Bristol Myers Squibb works through the Revlimid loss of exclusivity and prepares for the Eliquis and Opdivo LOEs, execution is key as it refills its pipeline with new launches and acquired assets.
Amgen Absorbs Horizon, Pitches Plans For New Rare Disease Growth Engine
Now that Amgen has completed its $27.8bn acquisition of Horizon, the company can focus on how it will turn Tepezza back into a growth product and maintain momentum for Krystexxa and other assets.
Amgen Falters In Core Immunology Business, But Help Is On The Horizon
Sales of Amgen’s key immunology drugs Otezla and Enbrel plunged in Q1, impacted by inventory and competition, but the company will add a new blockbuster when its Horizon acquisition closes in June.